SCHEDULE: Rani Therapeutics: Insider Boosts Stake, Governance Overhaul

Mir Imran, a key insider, increased his stake in Rani Therapeutics through a private placement, alongside proposed significant corporate governance changes.

Summary

• Mir Imran, a Director of Rani Therapeutics Holdings, Inc. and Managing Member of InCube Labs, L.L.C., purchased 2,083,334 shares of Class A Common Stock and 2,083,334 warrants in a private placement on October 23, 2025.
• The combined purchase price for the shares and accompanying warrants was $0.605 per unit, totaling $1,260,417.07, funded by Mr. Imran's personal funds.
• As of October 23, 2025, Mr. Imran beneficially owns 27,093,552 shares, representing 22.1% of the Class A Common Stock.
• InCube Labs, L.L.C. beneficially owns 22,424,788 shares (18.7%), InCube Ventures II, LP owns 301,710 shares (0.3%), and Rani Investment Corp. owns 7,694 shares (0.0%).
• The Issuer has agreed to amend its Certificate of Incorporation within 90 days of closing to reduce Class B Common Stock voting power from ten votes to one, eliminate stockholder action by written consent, and include additional stockholder protective provisions.
• Conforming changes to the Issuer's Bylaws and the Rani Therapeutics, LLC Limited Liability Company Agreement are also planned.
• The Tax Receivable Agreement, dated August 3, 2021, is slated for termination.
• The warrants have an exercise price of $0.48 per share, a five-year term, and require stockholder approval for issuance, which the Reporting Persons intend to support.
• The Issuer will file registration statements for the resale of private placement shares and underlying warrants within 15 days of closing, aiming for effectiveness within 45-90 days.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to significant insider buying, which signals confidence from a key individual. The proposed corporate governance enhancements, particularly the reduction of Class B voting power and inclusion of protective provisions, are generally favorable for common shareholders. However, the private placement's low per-unit price could be a concern regarding potential dilution for existing shareholders, preventing a higher score.

Positives

• Mir Imran, a significant insider, increased his beneficial ownership, signaling confidence in the company's future.
• Proposed corporate governance changes, such as reducing Class B voting power and adding stockholder protective provisions, could enhance shareholder rights and transparency for Class A shareholders.
• The termination of the Tax Receivable Agreement may simplify the company's financial structure.

Negatives

• The private placement price of $0.605 per share and warrant could be dilutive to existing shareholders if it is significantly below the prevailing market price.
• The need for substantial corporate governance amendments might suggest prior structural issues that required correction.

Risks

• The proposed corporate governance amendments and warrant issuance require stockholder approval, and failure to obtain this approval could impact the terms of the private placement and future capital structure.
• The Issuer's ability to use 'reasonable best efforts' to effect governance changes and registration statements does not guarantee their successful or timely completion.

Future Outlook

The Issuer plans to implement significant corporate governance changes, including amending its Certificate of Incorporation to reduce Class B voting power and eliminate stockholder action by written consent, within 90 days of the private placement closing. Stockholder approval will be sought for the issuance of shares underlying the warrants within 75 days. Additionally, the Issuer will file registration statements for the resale of the private placement securities within 15 days, aiming for effectiveness within 45-90 days.

Management Comments

• Mir Imran, as a Director and Managing Member of key entities, demonstrated his commitment by personally investing in the private placement.
• The Issuer's agreement to pursue significant corporate governance reforms and facilitate the registration of private placement shares reflects a strategic direction to align with investor interests and market standards.

Industry Context

This filing primarily details an insider transaction and corporate governance adjustments specific to Rani Therapeutics Holdings, Inc. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• N/A The filing does not contain specific comparisons to industry benchmarks, comparable companies, projects, or results.

Corporate Governance

Related Party Transactions

• Mir Imran, a Director of the Issuer and Managing Member of InCube Labs, L.L.C., purchased 2,083,334 shares and 2,083,334 warrants in a private placement.
• Mir Imran is the sole managing member of InCube Labs, L.L.C., which is wholly owned by him and his family.
• Mir Imran is a general partner of InCube Ventures II, LP and Rani Investment Corp.

Stakeholder Impact

• Shareholders: Class A shareholders may benefit from increased voting power and protective provisions due to governance changes, but could experience dilution from the private placement at a potentially lower price.
• Management: The changes in corporate governance structure will require management to adapt to new voting dynamics and potentially stricter operational guidelines.
• Investors in the private placement: These investors, including Mir Imran, will gain new shares and warrants, with the Issuer committed to facilitating registration for resale.

Next Steps

• The Issuer will amend its Certificate of Incorporation to effect governance changes within 90 days following the closing date of the private placement.
• The Issuer will make necessary conforming changes to its Amended and Restated Bylaws and the Rani Therapeutics, LLC Limited Liability Company Agreement.
• The Tax Receivable Agreement, dated August 3, 2021, will be terminated.
• The Issuer will seek stockholder approval for the issuance of shares underlying the warrants within 75 days following the closing of the private placement.
• The Issuer will file registration statements for the resale of the private placement shares and underlying warrants within 15 days of closing, aiming for effectiveness within 45-90 days.

Key Dates

Recommendation

The filing presents a mixed signal. On one hand, significant insider buying by Mir Imran indicates strong confidence in Rani Therapeutics' future, which is typically a positive indicator. The proposed corporate governance changes, particularly the reduction in Class B voting power and the addition of stockholder protective provisions, are generally favorable for Class A shareholders, potentially improving corporate transparency and accountability. However, the private placement occurred at a combined price of $0.605 per share and warrant, which could be significantly below the market price, potentially leading to dilution for existing shareholders. Without further information on the company's current valuation, market performance, and the full implications of the private placement's pricing relative to the market, a 'hold' recommendation is prudent. Investors should monitor the implementation of the governance changes and the market's reaction to the private placement.

Keywords

Rani Therapeutics, Mir Imran, Schedule 13D, Insider Buying, Private Placement, Corporate Governance, Class A Common Stock, Warrants, Shareholder Rights, SEC Filing